TreatGx supports the development of personalized treatment plans and prescribed medication options. It is a remarkable solution that is changing how we can help patients recover more quickly.
VANCOUVER, British Columbia (PRWEB) October 24, 2019
GenXys Health Care Systems is proud to share that Sun Life selected TreatGxplus as part of its disability management toolkit for plan sponsors. According to Sun Life, the goal is to help plan members get back to work faster and live healthier lives. The award-winning TreatGxplus solution, an advanced precision prescribing software including a pharmacogenetic test, is offered by LifeLabs, Canada’s largest diagnostic and laboratory company, in partnership with GenXys.
TreatGx, the precision prescribing application, presents over 40,000 prescription options and models out 250,000 drug interactions through its comprehensive and interactive online medication decision support engine. The cloud-based platform is accessible to patients and their healthcare providers across Canada and the United States.
"Identifying safe and effective medication options for the patient is the goal," said Dr. Martin Dawes, a Professor of Family Medicine, Chief Scientific Officer of GenXys."TreatGx helps us achieve that goal by supporting the development of personalized treatment plans and prescribed medication options. It is a remarkable solution that is changing how we can help patients recover more quickly."
The adoption of pharmacogenetic solutions by leading insurance companies such as Sun Life and UnitedHealth Group reaffirms the growing role of genetics in primary care and across health systems. With the level of clinical utility and relevance provided by TreatGx, pharmacogenetics can now enable medication decision support at the point of care.
While the initial Sun Life deployment will focus on mental health and chronic pain, TreatGx covers 35+ conditions where there are high levels of pharmacogenetic evidence. Echoing the recent statement by the Association for Molecular Pathology, every health-related pharmacogenetic link in TreatGx is supported by the best clinical evidence. For clinical accuracy and relevance, the solution also includes other variables such as other conditions, concurrent medications, and biophysical data in its proprietary algorithms that set it apart from others.
Building on significant growth in Canada, GenXys is establishing its footprint in the US through strong strategic partnerships. It is also working with stakeholders from healthcare systems and labs to incorporate clinically relevant pharmacogenetics at the point of care for ‘nextgen’ prescribing.
“We are delighted that the inclusion of pharmacogenetics in primary care is becoming a reality on a mass scale. It is the most applicable and actionable use of genetics for increasing patient safety, improving population health, and reducing the cost of healthcare,” said Karl Pringle, CEO of GenXys.
About GenXys Health Care Systems Inc.
GenXys offers best-in-class precision prescribing solutions to solve healthcare's most pressing challenges. Our precision prescribing software and pharmacogenetic solutions can prevent adverse drug reactions, a leading cause of death, and personalized drug selection to increase drug efficacy. Powering every prescription globally with our software improves patient safety, population health, and reduces healthcare costs.
For more information, please visit http://www.genxys.com.